JP2020532535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532535A5 JP2020532535A5 JP2020512443A JP2020512443A JP2020532535A5 JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5 JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sepiapterin
- composition according
- crystal
- tetrahydrobiopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023088749A JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553603P | 2017-09-01 | 2017-09-01 | |
| US62/553,603 | 2017-09-01 | ||
| US201862678069P | 2018-05-30 | 2018-05-30 | |
| US62/678,069 | 2018-05-30 | ||
| PCT/US2018/049359 WO2019046849A1 (en) | 2017-09-01 | 2018-09-04 | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Division JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532535A JP2020532535A (ja) | 2020-11-12 |
| JP2020532535A5 true JP2020532535A5 (https=) | 2021-10-14 |
| JP7811085B2 JP7811085B2 (ja) | 2026-02-04 |
Family
ID=65526057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512443A Active JP7811085B2 (ja) | 2017-09-01 | 2018-09-04 | セピアプテリンを含む医薬組成物及びその使用 |
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11752154B2 (https=) |
| EP (1) | EP3675863A4 (https=) |
| JP (2) | JP7811085B2 (https=) |
| CN (1) | CN111491635A (https=) |
| CA (1) | CA3073957A1 (https=) |
| MX (1) | MX2020002271A (https=) |
| WO (1) | WO2019046849A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) * | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
| EP4093405A1 (en) | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
| WO2021168206A1 (en) * | 2020-02-19 | 2021-08-26 | Musc Foundation For Research Development | L-sepiapterin and methods of use for treating diseases and disorders |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| IL305037A (en) | 2021-02-09 | 2023-10-01 | Ptc Therapeutics Mp Inc | Methods of treating glioblastomas with spiafatrin |
| PE20241579A1 (es) | 2021-09-29 | 2024-08-01 | Ptc Therapeutics Inc | Composicion farmaceutica de sepiapterina |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| EP0722731B1 (en) | 1994-08-05 | 2002-06-05 | Suntory Limited | Remedy for spinocerebellar degeneration |
| JP2002515965A (ja) | 1995-08-18 | 2002-05-28 | ダブリュー． ランドリ，ドナルド | 抗体触媒反応の調節による有機化合物の検出 |
| US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| GB0116620D0 (en) | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| ITMI20011732A1 (it) | 2001-08-07 | 2003-02-07 | Indena Spa | Composizioni farmaceutiche e/o cosmetiche orali per il trattamento e la prevenzione di disturbi del cuoio capelluto |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007509909A (ja) | 2003-10-31 | 2007-04-19 | アルタナ ファルマ アクチエンゲゼルシャフト | 呼吸器疾患の治療のためのｂｈ４の使用 |
| JP5184783B2 (ja) | 2003-11-17 | 2013-04-17 | バイオマリン ファーマシューティカル インコーポレイテッド | テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法 |
| EP1687308B1 (en) | 2003-11-17 | 2019-06-12 | Merck & Cie | Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| BRPI0609421B1 (pt) | 2005-04-28 | 2021-06-01 | Shiratori Pharmaceutical Co., Ltd. | Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona |
| US20080075666A1 (en) * | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| LT2545939T (lt) | 2007-04-11 | 2021-03-10 | Biomarin Pharmaceutical Inc. | Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu |
| EA017064B1 (ru) | 2008-03-10 | 2012-09-28 | Такеда Фармасьютикал Компани Лимитед | Кристаллическое производное бензимидазола |
| WO2010017570A2 (de) * | 2008-08-12 | 2010-02-18 | Orpha Swiss Gmbh | Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin |
| CN102256976A (zh) | 2008-12-23 | 2011-11-23 | 贝林格尔.英格海姆国际有限公司 | 有机化合物的盐形式 |
| JP2012533633A (ja) | 2009-07-20 | 2012-12-27 | ベテゲン・エルエルシー | 経口投与のための安定な薬学的オメプラゾール製剤 |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| CN104736539B (zh) * | 2012-05-07 | 2017-09-01 | 白鸟制药株式会社 | 墨蝶呤和四氢乳酰蝶呤的制造法 |
| ES2586945T3 (es) * | 2014-03-31 | 2016-10-19 | Vasopharm Gmbh | Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones |
| DK3546464T3 (da) | 2014-05-12 | 2020-07-27 | Alfasigma Spa | Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| JP2018531964A (ja) | 2015-10-27 | 2018-11-01 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 液体ブプレノルフィン製剤 |
| JP6967334B2 (ja) | 2015-12-21 | 2021-11-17 | 備前化成株式会社 | 高度不飽和脂肪酸のエステルを含む組成物 |
| EP3468534A4 (en) | 2016-06-13 | 2020-02-05 | Meharry Medical College | MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH |
| WO2018019931A1 (en) * | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| JP7811085B2 (ja) | 2017-09-01 | 2026-02-04 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | セピアプテリンを含む医薬組成物及びその使用 |
| AU2019277372B2 (en) | 2018-05-30 | 2024-12-19 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| FI3801536T3 (fi) | 2018-05-30 | 2024-08-29 | Ptc Therapeutics Mp Inc | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi |
| EP3801534B1 (en) | 2018-05-30 | 2026-02-18 | PTC Therapeutics MP, Inc. | Treatment of phenylketonuria with sepiapterin |
| IL290321B1 (en) | 2019-08-05 | 2026-04-01 | Ptc Therapeutics Inc | Use of spiapterin and its metabolites for radiation exposure treatment |
| IL291565B1 (en) | 2019-09-25 | 2026-04-01 | Ptc Therapeutics Inc | Method for treating phenylalanine irregularity |
-
2018
- 2018-09-04 JP JP2020512443A patent/JP7811085B2/ja active Active
- 2018-09-04 EP EP18850633.1A patent/EP3675863A4/en active Pending
- 2018-09-04 CA CA3073957A patent/CA3073957A1/en active Pending
- 2018-09-04 MX MX2020002271A patent/MX2020002271A/es unknown
- 2018-09-04 WO PCT/US2018/049359 patent/WO2019046849A1/en not_active Ceased
- 2018-09-04 CN CN201880070952.7A patent/CN111491635A/zh active Pending
-
2019
- 2019-10-31 US US16/670,362 patent/US11752154B2/en active Active
-
2023
- 2023-05-30 JP JP2023088749A patent/JP2023116556A/ja active Pending
- 2023-08-18 US US18/235,486 patent/US12213982B2/en active Active
-
2024
- 2024-12-20 US US18/990,477 patent/US20250195526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532535A5 (https=) | ||
| HRP20230931T1 (hr) | Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida | |
| JP2021527031A5 (https=) | ||
| ES2947819T3 (es) | Método para el tratamiento del cáncer con N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-carboxamida | |
| JP2021505575A5 (https=) | ||
| JP2024063143A5 (https=) | ||
| JP2015509972A5 (https=) | ||
| JP2009506014A5 (https=) | ||
| AU2012335981C1 (en) | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | |
| BR112012003592B1 (pt) | composição farmacêutica contendo derivado de quinolina | |
| HRP20240033T1 (hr) | Formulacija koja sadrži inhibitor mek | |
| JP2015511621A5 (https=) | ||
| JP2017537899A5 (https=) | ||
| EA032421B1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2018168191A5 (https=) | ||
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| JP2016503010A5 (https=) | ||
| BR112013031712B1 (pt) | Composto 4-hidróxi-5-metóxi-n,1-dimetil-2-oxo-n-[(4-trifluorometil) -fenil] -1,2-diidroquinolino-3- carboxamida enriquecido em deutério, seu uso, composição farmacêutica, e, método para preparar um composto | |
| JP2016006070A (ja) | Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ | |
| JP2008528542A5 (https=) | ||
| JPWO2009038112A1 (ja) | Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤 | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| JP2011530540A5 (https=) | ||
| WO2017041680A1 (zh) | 一种沃替西汀或其盐的药用组合物及其制备方法 | |
| AU2019338483B2 (en) | Combination therapy for the treatment of prostate cancer |